AAV Vectors for Adipose Tissue Transduction

The patent applies local quality by using adipose tissue-specific regulatory elements (promoters and enhancers) that are inserted into the AAV vector construct. These regulatory elements ensure that the transgene is expressed only in adipose tissue cells, creating local specificity at the molecular level. The regulatory elements include adipose-specific promoters such as aP2, FABP4, and PPARγ promoters, which are activated only in adipose tissue, thereby confining gene expression to the target tissue while maintaining high transduction efficiency throughout the adipose tissue.

The patent uses adipose tissue-specific regulatory elements as intermediaries between the AAV vector and the transgene expression. These regulatory elements act as molecular mediators that allow the vector to deliver the gene broadly to adipose tissue throughout the body while preventing expression in non-adipose tissues. The regulatory elements include tissue-specific promoters and enhancers that recognize and bind only to adipose tissue cellular machinery, thus mediating selective expression and eliminating harmful off-target effects in organs such as the liver and heart.

The patent applies parameter changes by modifying the AAV vector construct to include specific regulatory elements that enhance transduction efficiency. The regulatory elements include adipose-specific promoters, enhancers, and response elements that are incorporated into the vector genome. These parameter changes at the molecular level dramatically improve transduction efficiency in adipose tissue compared to conventional methods, while the overall approach remains a standardized viral vector delivery system that can be administered through established routes.